Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma

John Edward Janik, John C. Morris, Stefania Pittaluga, Kristin McDonald, Mark Raffeld, Elaine S. Jaffe, Nicole Grant, Martin Gutierrez, Thomas A. Waldmann, Wyndham H. Wilson

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Levels of serum soluble interleukin 2 receptor (sIL-2R) provide a reliable marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia/ lymphoma. The malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and are usually positive for expression of CD25. We measured serum sIL-2R and soluble CD30 (sCD30) levels in patients with ALCL treated with EPOCH (etoposide, prednisone, Oncovin, Cytoxan, hydroxydaunorubicin) infusional chemotherapy. Serum sCD30 levels were elevated and decreased in response to therapy as previously reported. Serum sIL-2R levels were elevated in 7 of 9 patients with ALCL and decreased in response to treatment. Baseline serum sIL-2R levels varied but correlated well with serum sCD30 levels (r = 0.97). Patients positive for the anaplastic lymphoma kinase (ALK) gene showed elevated sIL-2R levels, whereas those negative for ALK had normal serum sIL-2R levels and their tumors lacked CD25 expression. Serum sIL-2R levels were elevated in both patients with recurrent disease.

Original languageEnglish (US)
Pages (from-to)3355-3357
Number of pages3
JournalBlood
Volume104
Issue number10
DOIs
StatePublished - Nov 15 2004

Fingerprint

Anaplastic Large-Cell Lymphoma
Interleukin-2 Receptors
Serum
Chemotherapy
T-cells
Hairy Cell Leukemia
Adult T Cell Leukemia Lymphoma
Vincristine
Etoposide
Prednisone
Cyclophosphamide
Tumors
Genes
Drug Therapy

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Janik, J. E., Morris, J. C., Pittaluga, S., McDonald, K., Raffeld, M., Jaffe, E. S., ... Wilson, W. H. (2004). Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood, 104(10), 3355-3357. https://doi.org/10.1182/blood-2003-11-3922

Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. / Janik, John Edward; Morris, John C.; Pittaluga, Stefania; McDonald, Kristin; Raffeld, Mark; Jaffe, Elaine S.; Grant, Nicole; Gutierrez, Martin; Waldmann, Thomas A.; Wilson, Wyndham H.

In: Blood, Vol. 104, No. 10, 15.11.2004, p. 3355-3357.

Research output: Contribution to journalArticle

Janik, JE, Morris, JC, Pittaluga, S, McDonald, K, Raffeld, M, Jaffe, ES, Grant, N, Gutierrez, M, Waldmann, TA & Wilson, WH 2004, 'Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma', Blood, vol. 104, no. 10, pp. 3355-3357. https://doi.org/10.1182/blood-2003-11-3922
Janik JE, Morris JC, Pittaluga S, McDonald K, Raffeld M, Jaffe ES et al. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood. 2004 Nov 15;104(10):3355-3357. https://doi.org/10.1182/blood-2003-11-3922
Janik, John Edward ; Morris, John C. ; Pittaluga, Stefania ; McDonald, Kristin ; Raffeld, Mark ; Jaffe, Elaine S. ; Grant, Nicole ; Gutierrez, Martin ; Waldmann, Thomas A. ; Wilson, Wyndham H. / Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. In: Blood. 2004 ; Vol. 104, No. 10. pp. 3355-3357.
@article{d7e976bb997146ac91073224f65871ab,
title = "Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma",
abstract = "Levels of serum soluble interleukin 2 receptor (sIL-2R) provide a reliable marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia/ lymphoma. The malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and are usually positive for expression of CD25. We measured serum sIL-2R and soluble CD30 (sCD30) levels in patients with ALCL treated with EPOCH (etoposide, prednisone, Oncovin, Cytoxan, hydroxydaunorubicin) infusional chemotherapy. Serum sCD30 levels were elevated and decreased in response to therapy as previously reported. Serum sIL-2R levels were elevated in 7 of 9 patients with ALCL and decreased in response to treatment. Baseline serum sIL-2R levels varied but correlated well with serum sCD30 levels (r = 0.97). Patients positive for the anaplastic lymphoma kinase (ALK) gene showed elevated sIL-2R levels, whereas those negative for ALK had normal serum sIL-2R levels and their tumors lacked CD25 expression. Serum sIL-2R levels were elevated in both patients with recurrent disease.",
author = "Janik, {John Edward} and Morris, {John C.} and Stefania Pittaluga and Kristin McDonald and Mark Raffeld and Jaffe, {Elaine S.} and Nicole Grant and Martin Gutierrez and Waldmann, {Thomas A.} and Wilson, {Wyndham H.}",
year = "2004",
month = "11",
day = "15",
doi = "10.1182/blood-2003-11-3922",
language = "English (US)",
volume = "104",
pages = "3355--3357",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma

AU - Janik, John Edward

AU - Morris, John C.

AU - Pittaluga, Stefania

AU - McDonald, Kristin

AU - Raffeld, Mark

AU - Jaffe, Elaine S.

AU - Grant, Nicole

AU - Gutierrez, Martin

AU - Waldmann, Thomas A.

AU - Wilson, Wyndham H.

PY - 2004/11/15

Y1 - 2004/11/15

N2 - Levels of serum soluble interleukin 2 receptor (sIL-2R) provide a reliable marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia/ lymphoma. The malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and are usually positive for expression of CD25. We measured serum sIL-2R and soluble CD30 (sCD30) levels in patients with ALCL treated with EPOCH (etoposide, prednisone, Oncovin, Cytoxan, hydroxydaunorubicin) infusional chemotherapy. Serum sCD30 levels were elevated and decreased in response to therapy as previously reported. Serum sIL-2R levels were elevated in 7 of 9 patients with ALCL and decreased in response to treatment. Baseline serum sIL-2R levels varied but correlated well with serum sCD30 levels (r = 0.97). Patients positive for the anaplastic lymphoma kinase (ALK) gene showed elevated sIL-2R levels, whereas those negative for ALK had normal serum sIL-2R levels and their tumors lacked CD25 expression. Serum sIL-2R levels were elevated in both patients with recurrent disease.

AB - Levels of serum soluble interleukin 2 receptor (sIL-2R) provide a reliable marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia/ lymphoma. The malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and are usually positive for expression of CD25. We measured serum sIL-2R and soluble CD30 (sCD30) levels in patients with ALCL treated with EPOCH (etoposide, prednisone, Oncovin, Cytoxan, hydroxydaunorubicin) infusional chemotherapy. Serum sCD30 levels were elevated and decreased in response to therapy as previously reported. Serum sIL-2R levels were elevated in 7 of 9 patients with ALCL and decreased in response to treatment. Baseline serum sIL-2R levels varied but correlated well with serum sCD30 levels (r = 0.97). Patients positive for the anaplastic lymphoma kinase (ALK) gene showed elevated sIL-2R levels, whereas those negative for ALK had normal serum sIL-2R levels and their tumors lacked CD25 expression. Serum sIL-2R levels were elevated in both patients with recurrent disease.

UR - http://www.scopus.com/inward/record.url?scp=8644228628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8644228628&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-11-3922

DO - 10.1182/blood-2003-11-3922

M3 - Article

VL - 104

SP - 3355

EP - 3357

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -